Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading
Loading
Home
News
Emm raises $9M seed to create one of the world’s first ‘smart’ menstrual cups

From TechCrunch

By Dominic-Madori Davis

November 19, 2025

Emm raises $9M seed to create one of the world’s first ‘smart’ menstrual cups

Emm raises $9M seed to create one of the world’s first ‘smart’ menstrual cups

Jenny Button first thought of Emm during the COVID lockdown. She was using an Oura ring and the Whoop monitoring band and getting insights about her body, but there wasn’t a device that could provide data about one of the most important aspects — reproductive and menstrual health.  

“It seemed crazy to me, because these are things that every woman wants to be able to track and better understand,” she told TechCrunch. She thought, “Why not make a wearable device that can tell someone more about their reproductive health?” She penned a letter to one of the engineers at Dyson, made a connection, and started testing the idea.  

“Five years later, following thousands of designs and iterations and extended user testing, we’ve revealed the world’s first smart menstrual cup,” said Button.  

The U.K.-based company has also raised a $9 million (£6.8 million) seed round, one led by Lunar Ventures, as it prepares to officially launch its product next year.  

The product functions like a regular menstrual cup — designed to store period blood rather than absorb it. But Emm’s medical-grade silicone is “fitted with ultra-thin, advanced sensor technology.” This sensor gathers data that will help users understand patterns about their cycles. Button hopes that it could “transform the research, diagnosis and treatment of menstrual and reproductive health conditions.”  

She isn’t the only one who thinks this way. Other women’s health founders told The Guardian a few months ago that menstrual blood was an “overlooked opportunity in women’s health” that could offer insights not available from health tests based on circulatory blood. 

It could, for instance, help diagnose painful and often misdiagnosed medical conditions like endometriosis.  

“One in 10 women today suffer from endometriosis,” Button said. “A condition that, like many others in reproductive health, takes an average of seven to 10 years to diagnose.” 

That delay “is largely due to the lack of meaningful data and poor characterization of menstrual health in clinical settings,” Button believes. “There have been no reliable tools to accurately and objectively track that aspect of health until now.” 

Beyond endometriosis, she added that one in three women experiences “severe reproductive health issues” throughout their lives.  

Data gathered from the Emm app is encrypted and stored securely, with two-factor authentication. “It’s also always anonymized or pseudonymized,” meaning personal identifiers are removed or replaced with codes, “and will only be accessed by the people at Emm who genuinely need it,” she said. 

Button used the word “strategic” to describe her funding round and said she connected with her lead investor through her network. Others in the round include Alumni Ventures (who backed Oura), the Labcorp Venture Fund and Blue Lion Global. Money will be used to launch the product into the U.K. market next year, she said, adding that the waitlist has already topped 30,000, with preorders to go live soon.  

Capital will also be used for research and development. Button hopes to enter the U.S. market in early 2027.  

“Menstrual health is only the jumping off point for Emm,” said Button. “Ultimately, I believe we will have a profound impact on women’s health more broadly,” she continued, adding she hopes to expand the product one day, perhaps into diagnosis, other digital care tools, and even therapeutics.  

“Our mission is to accelerate diagnosis, equip people with the data to advocate for themselves, and ultimately help them take control of their own bodies and health journeys,” she said. 

View original article on techcrunch.com

Most Recent

Neil Rimer thinks the AI money is coming back out

Neil Rimer thinks the AI money is coming back out

Neil Rimer, the venture capitalist who co-founded Index Ventures, predicts the historic wealth AI is generating in Silicon Valley will have to be redistributed, voluntarily or involuntarily.

Jul 17, 2026

Databricks hits $188B valuation, extending its run as AI’s favorite second act

Databricks hits $188B valuation, extending its run as AI’s favorite second act

Databricks has remade its image into an AI company and has published research on the cost savings of open weight AI models for coding.

Jul 17, 2026

Nuclear startup Valar Atomics in talks to raise new funding at $6B valuation

Nuclear startup Valar Atomics in talks to raise new funding at $6B valuation

The potential deal highlights a growing trend of complex, multi-stage funding rounds that mask true entry prices.

Jul 17, 2026

Founders Fund hires former OpenAI exec Ryan Beiermeister (and not because of her ‘Mafia’ skills)

Founders Fund hires former OpenAI exec Ryan Beiermeister (and not because of her ‘Mafia’ skills)

Ryan Beiermeister, who demonstrated cool analysis in the Founders Fund YouTube series "Mafia," has joined the firm as a partner.

Jul 16, 2026

Similar Posts

Prickly Pear Health will showcase how it’s helping women’s brain health at TechCrunch Disrupt 2025

Prickly Pear Health will showcase how it’s helping women’s brain health at TechCrunch Disrupt 2025

Prickly Pear Health provides medical support for women’s brain health, a voice-first, AI-powered companion that helps women in their 30s to 50s navigate the hormonal changes that affect brain health.

Oct 1, 2025

Alloy Women’s Health is making menopausal care accessible

Alloy Women’s Health is making menopausal care accessible

This week on found, Dom and Becca are talking with the co-founders of Alloy Women’s Health. The startup just closed a new funding round to expand its mission of fixing menopause care. Alloy founders, Monica Molenaar and Anne Fulenwider, discussed raising capital in a competitive health tech landscape, their choice to bypass traditional insurance models, and how this funding will help them scale their telehealth platform nationally. They also discuss: How their co-CEO model was a natural fit

Nov 26, 2024

Mira is helping fill the hormone knowledge gap for women and the medical industry

Mira is helping fill the hormone knowledge gap for women and the medical industry

Hormones play a massive role in when and how easily women can get pregnant, but research and resources in this area are lacking. Mira is looking to change that. Mira is an at-home, palm-sized hormone testing device women use to test their urine for their hormone levels. Mira’s corresponding app deciphers their results and spots patterns which help women better plan for the right time to try to get pregnant or know when it’s time to bring up potential issues with their doctor. Sylvia Kang, the c

Sep 10, 2024

The wild story of how gut health AI toilet startup Throne raised $4M led by Moxxie

The wild story of how gut health AI toilet startup Throne raised $4M led by Moxxie

The tale of how smart toilet startup Throne landed its seed round is so full of serendipities, one could almost believe it was orchestrated by the hand of

May 22, 2025

Most Recent

Neil Rimer thinks the AI money is coming back out

Neil Rimer thinks the AI money is coming back out

Neil Rimer, the venture capitalist who co-founded Index Ventures, predicts the historic wealth AI is generating in Silicon Valley will have to be redistributed, voluntarily or involuntarily.

Jul 17, 2026

Databricks hits $188B valuation, extending its run as AI’s favorite second act

Databricks hits $188B valuation, extending its run as AI’s favorite second act

Databricks has remade its image into an AI company and has published research on the cost savings of open weight AI models for coding.

Jul 17, 2026

Nuclear startup Valar Atomics in talks to raise new funding at $6B valuation

Nuclear startup Valar Atomics in talks to raise new funding at $6B valuation

The potential deal highlights a growing trend of complex, multi-stage funding rounds that mask true entry prices.

Jul 17, 2026

Founders Fund hires former OpenAI exec Ryan Beiermeister (and not because of her ‘Mafia’ skills)

Founders Fund hires former OpenAI exec Ryan Beiermeister (and not because of her ‘Mafia’ skills)

Ryan Beiermeister, who demonstrated cool analysis in the Founders Fund YouTube series "Mafia," has joined the firm as a partner.

Jul 16, 2026

Similar Posts

Prickly Pear Health will showcase how it’s helping women’s brain health at TechCrunch Disrupt 2025

Prickly Pear Health will showcase how it’s helping women’s brain health at TechCrunch Disrupt 2025

Prickly Pear Health provides medical support for women’s brain health, a voice-first, AI-powered companion that helps women in their 30s to 50s navigate the hormonal changes that affect brain health.

Oct 1, 2025

Alloy Women’s Health is making menopausal care accessible

Alloy Women’s Health is making menopausal care accessible

This week on found, Dom and Becca are talking with the co-founders of Alloy Women’s Health. The startup just closed a new funding round to expand its mission of fixing menopause care. Alloy founders, Monica Molenaar and Anne Fulenwider, discussed raising capital in a competitive health tech landscape, their choice to bypass traditional insurance models, and how this funding will help them scale their telehealth platform nationally. They also discuss: How their co-CEO model was a natural fit

Nov 26, 2024

Mira is helping fill the hormone knowledge gap for women and the medical industry

Mira is helping fill the hormone knowledge gap for women and the medical industry

Hormones play a massive role in when and how easily women can get pregnant, but research and resources in this area are lacking. Mira is looking to change that. Mira is an at-home, palm-sized hormone testing device women use to test their urine for their hormone levels. Mira’s corresponding app deciphers their results and spots patterns which help women better plan for the right time to try to get pregnant or know when it’s time to bring up potential issues with their doctor. Sylvia Kang, the c

Sep 10, 2024

The wild story of how gut health AI toilet startup Throne raised $4M led by Moxxie

The wild story of how gut health AI toilet startup Throne raised $4M led by Moxxie

The tale of how smart toilet startup Throne landed its seed round is so full of serendipities, one could almost believe it was orchestrated by the hand of

May 22, 2025